By admin 
NRx Prescription drugs, Inc. (NASDAQ:NRXP) Q1 2025 Earnings Convention Name Might 15, 2025 4:30 PM ET
Firm Members
Matthew Duffy – Chief Enterprise Officer
Jonathan Javitt – Founder, Chairman, and Chief Government Officer
Michael Abrams – Chief Monetary Officer
Convention Name Members
Tom Shrader – BTIG
Ed Woo – Ascendiant Capital
Operator
Good afternoon, girls and gents, and welcome to the NRx Prescription drugs First Quarter 2025 Earnings Name. Presently, all strains are in a listen-only mode. Following the presentation, we’ll conduct a question-and-answer session. [Operator Instructions] This name is being recorded on Thursday, Might 15, 2025.
I’d now like to show the convention over to Matthew Duffy, Chief Enterprise Officer. Please go forward.
Matthew Duffy
Thanks, Andrew, and welcome, everybody. Earlier than we proceed with the decision, I want to remind everybody that sure statements made throughout this name are forward-looking statements underneath U.S. federal securities legal guidelines. These statements are topic to dangers and uncertainties that might trigger precise outcomes to vary materially from historic expertise or current expectations. Further data regarding components that might trigger precise outcomes to vary from statements made on this name is contained in our periodic experiences filed with the SEC. The forward-looking statements made throughout this name converse solely as of the date hereof, and the corporate undertakes no obligation to replace or revise the forward-looking statements.
Data offered on this name is contained within the press launch issued in the present day and the corporate’s Kind 10-Q, which can be accessed from the Traders web page of the NRx Prescription drugs web site. Becoming a member of me in the present day on the decision are Jonathan Javitt, our Founder, Chairman, and CEO; and Michael Abrams, our Chief Monetary Officer. Dr. Javitt will present an outline of our firm’s progress as reported in in the present day’s Kind 10-Q, following which Mike will evaluation our firm’s monetary outcomes. Following their ready remarks, we’ll handle investor